Company: PTHS
Filing Date: 2025-11-25
Form Type: DEF 14A
Source: 0001753926-25-001827
Chunk: 10

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-11-25
Form: DEF 14A
Chunk 10
---
 other persons as the Board may recommend, unless the Board
reduces the number of directors. We have no reason to believe that any nominee will be unable or unwilling to serve if elected
as a director.

| Name                  
 of Director           |     | Age |     | Director     
 Since        |
| Peter                 
 Greenleaf(3)          |     |  55 |     | Chairman     
 of the Board |
| Richard               
 Baxter                |     |  62 |     | Director     |
| Todd                  
 Davis                 |     |  64 |     | Director     |
| Ezra                  
 Friedberg(1)          |     |  55 |     | Director     |
| Dr.                   
 Richard Malamut(2)(3) |     |  66 |     | Director     |
| Matthew               
 Pauls(1)(2)           |     |  54 |     | Director     |
| Scott                 
 Plesha                |     |  61 |     | Director     |

| (1) | Member                  
 of the audit committee. |

| (2) | Member                         
 of the compensation committee. |

| (3) | Member                                                
 of the nominating and corporate governance committee. |

Peter Greenleafhas served as the Chief Executive Officer and member of the board of directors of Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, since April 2019. From March 2018 to April 2019, he served as the CEO of Cerecor Pharmaceuticals, Inc. (now Avalo Therapeutics, Inc.). From March 2014 to February 2018, Mr. Greenleaf served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to UK pharmaceutical company, Mallinckrodt PLC. From June 2013 to March 2014, he served as CEO and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, he also served as President of MedImmune Ventures, a